CNSP

CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM

CNSP Stock Price Increases Over 15%: Why It Happened

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook